Pardes Biosciences, Inc.

NasdaqGM:PRDS Stock Report

Market Cap: US$131.2m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Pardes Biosciences Past Earnings Performance

Past criteria checks 0/6

Pardes Biosciences's earnings have been declining at an average annual rate of -1.6%, while the Biotechs industry saw earnings growing at 23.7% annually.

Key information

-1.6%

Earnings growth rate

45.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth raten/a
Return on equity-49.0%
Net Marginn/a
Last Earnings Update30 Jun 2023

Recent past performance updates

No updates

Recent updates

We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

Jul 18
We're Keeping An Eye On Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Rate

Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

Jan 20
Here's Why We're Watching Pardes Biosciences' (NASDAQ:PRDS) Cash Burn Situation

We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Oct 01
We Think Pardes Biosciences (NASDAQ:PRDS) Needs To Drive Business Growth Carefully

Pardes begins phase 2 trial of oral drug PBI-0451 for COVID-19

Sep 13

Pardes Biosciences GAAP EPS of -$0.48

Aug 15

Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

Jun 14
Pardes Biosciences (NASDAQ:PRDS) Is In A Good Position To Deliver On Growth Plans

Pardes Biosciences: Advancing A Viral Protease Inhibitor Platform

Jan 21

Revenue & Expenses Breakdown

How Pardes Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:PRDS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-762657
31 Mar 230-932870
31 Dec 220-972970
30 Sep 220-872761
30 Jun 220-752352
31 Mar 220-551738
31 Dec 210-391028
30 Sep 210-36721
30 Jun 210-27415
31 Mar 210-2029

Quality Earnings: PRDS is currently unprofitable.

Growing Profit Margin: PRDS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PRDS's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare PRDS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRDS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-31.3%).


Return on Equity

High ROE: PRDS has a negative Return on Equity (-49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/09/01 05:35
End of Day Share Price 2023/08/30 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pardes Biosciences, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuchen DingJefferies LLC
Douglas BuchananJMP Securities
Roanna Clarissa RuizLeerink Partners LLC